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Preface 
 
In the world of scientific publication, morals are not completely different 
than in daily life. There are cases of clear research misconduct; they are se-
rious, but few. If misconduct occurs, it creates a disruption, not only for the 
scientific community and their institutions, but for all individuals involved. 
Relationships of personal trust are broken, academic careers may be termi-
nated. Apart from cases of clear misconduct, there are also questionable 
research practices. This is a huge area, with which all scientists are con-
fronted in their daily work. Perhaps a researcher cannot remember the 
source of a quotation – could it not just as easily be his own thought? Why 
shouldn’t a scientist do a colleague a favour by adding his name to a paper? 
It is, however, not only the question as to what the right thing to do is, but 
also as to what is appropriate in a given situation. As Cicero said, “nothing 
is more difficult than recognising what is appropriate” (Orator 21,70). There 
are moral problems and ethical questions in scientific publication – we 
should talk about them.  
 
Sabine Kleinert gave a talk and shared her experiences as a medical editor 
with publication ethics issues as well as her general view on research integ-
rity in a panel discussion on 30 September 2009 at the UZH Irchel. We have 
published a transcript of her talk that reflects the style of spoken language. 
Irene Knüsel participated in the panel discussion as a young academic and 
has contributed a summary of her view from the benchside: “Science today 
is like driving on a busy highway.” Frank Rühli and Nikola Biller-Andorno 
initiated the panel discussion as members of the Ethics Committee UZH. 
 
I am grateful to Janine Hall for the transcription of Sabine Kleinert’s talk, to 
Martina Arioli and Sandra Weiser for editorial help and to Mary Carozza 
and Alexander Borbély for the corrections. 
 
Zurich, in February 2010, Hans-Ulrich Rüegger 
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Introduction 
 
by Nikola Biller-Andorno and Frank Rühli 
 
Falsified data, manipulated analyses, illegitimate authorship – the issue of 
scientific misconducts arises time and again in the media. Such scandals can 
have considerable consequences for a discipline, particularly if the field of 
research itself is controversial, as was the case with “Hwang-gate”, which 
occurred at a time of fierce public controversy over the moral legitimacy of 
human embryonic stem cell research. 
 
Most of the time, however, instances of misconduct tend to be forgotten 
after a few weeks, perhaps leaving a vague sense of public mistrust in sci-
ence in general and scientists in particular. Yet, public attention generally 
moves on to other topics, and researchers get back to business as usual. 
 
There is, however, a danger in this way of handling the phenomenon. For 
one, it can reasonably be assumed that the scandals hitting the news may be 
nothing but the tip of the iceberg, leaving many instances of scientific mis-
conduct undiscovered. Despite discussions among scientists (e.g. Paalman 
2000, Wilmshurst 1997), no reliable statistics exist on issues of misconduct 
– neither in Switzerland nor internationally. Yet, an experiment substanti-
ated that two-thirds of intentional major errors in a fake manuscript were not 
noticed by reviewers (Baxt et al. 1998). 
 
Secondly, we need to turn our attention to those practices that are in the grey 
zone between proper and improper conduct. Many such grey areas have 
been clarified in recent years through agreements made for dealing with the 
issues. Some of these agreements are limited to certain areas – e.g. author-
ship criteria in medical sciences. Theoretically – at least for issue of publica-
tion – proper conduct has been clearly defined by the Vancouver conven-
tion. And yet, the convention is often not implemented correctly (Goodman 
1994). However, with interdisciplinary projects becoming more and more 
common, it will become increasingly necessary to discuss and – where it 
makes sense – to harmonise varying scientific cultures with respect to the 
issue of proper conduct. 
 
Last, and possibly most important, we tend to miss the chance to discuss the 
underlying reasons for such cases happening in the first place: Are they only 
caused by extraordinarily greedy, ambitious individuals, or are there struc-
tural factors fostering such an unfortunate development? Does the climate of 
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continuous competition, as well as the focus on grant acquisition and high-
impact publication, lead to an environment in which the threshold for scien-
tific misconduct is rather low? Does this create an environment in which it 
may, in reality, be considered a smart move to not take the rules too seri-
ously? Perhaps we ought to reassess whether our current expectations are 
realistic and whether a “normal” academic career can legitimately include 
phases of diminished output, of experimenting with something that turns out 
to be unsuccessful or even lack innovation. Perhaps we need to question 
whether negative results really mean “no results” at all. We may find that 
acknowledging apparent detours, negative results and less productive phases 
may actually lead to more sustainable careers as well as a richer and possi-
bly better science.  
 
Proper scientific conduct cannot be learned by simply studying guidelines. It 
needs to be lived in the lab or in the group. Young scholars must learn from 
their superiors that scientific integrity is not an ideal irrelevant to their prac-
tice in real life, but that it belongs to the heart of science. The loss of scien-
tific integrity not only ruins public trust, it also renders scientific progress 
inefficient, if not impossible. 
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Research Integrity and Publication Ethics: 
Common Transgressions and Solutions 
 
by Sabine Kleinert 
 
Introduction 
 
Publication ethics is one of my great passions. I hope at the end of this eve-
ning it will become one of yours as well. I want to not only share with you 
my experience as an editor with publication ethics issues, but also my gen-
eral view on research integrity. Because I don’t think research integrity and 
publication ethics are two different things, there is definitely an overlap. But 
what is important is that, as editors, we are often the first people who will 
see that something is wrong with research and the way it has been con-
ducted. Yes, there are the pure publication ethics issues such as duplicate 
publications, such as authorship issues. But we also often get confronted 
with papers where we say: “How did this go through an ethics committee?” 
“How on earth did patients give consent to these kinds of procedures?” So 
there is a huge overlap.  
 
The research environment in which I did research – it’s now something like 
fifteen years ago – was different. I think there was less pressure. Now there 
is pressure to publish – publish or perish. The first question when applying 
for a position is: “What’s your publication list?” There is intense pressure 
and competition for funding, for career progression. Then there is the issue 
of conflict of interest. Researchers are increasingly expected to have com-
mercial interest, be it imposed by the university or be it by companies that 
approach you and enthuse you with lots of money, travels, gifts and so on. 
There are many guidelines and rules out there by which we are meant to 
abide. Collaborations are also relevant – research is not done anymore by 
one or two people in one lab. It is done between departments, between uni-
versities, between different cities in countries, and between groups in differ-
ent countries or continents. There is intense competition, not only between 
individuals but also between disciplines and between institutions. 
 
So, what I will talk about is not only publication ethics but also a moral and 
ethical framework of integrity. Then I would like to briefly discuss what I 
think research misconduct is. How big a problem is it? What are the com-
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mon scenarios and what has my experience with misconduct been? What 
solutions do I see – either on the part of editors, institutions or the research-
ers themselves. How can we foster integrity? We want to prevent miscon-
duct and I believe the ultimate goal ought to be to foster an environment of 
integrity. 
 
Moral and ethical framework of integrity 
 
The work environment is a hugely influential factor in terms of integrity. If 
you work in a lab where your supervisor doesn’t take things so seriously, 
then you learn that this is the accepted way of doing research. If you are in 
an institution where people get away with gift authorship all the time, you 
probably won’t think there’s anything wrong with it. There’s also the big 
issue about how to deal with whistleblowers. It’s easy to see things and then 
to look away.  
 
Lawrence Kohlberg was an American developmental philosopher who re-
searched the stages of moral development in human beings. According to 
him, development goes from obedience – “How can I avoid detection and 
punishment?” (the typical infantile stage) – to self-interest as a child – 
“What is in it for me?” – to conformity due to interpersonal relationships – 
“What is everyone else doing?” That’s the teenage stage. Then it moves on 
to law and order as a young adult and, ideally, there will be a social contract 
for the greater good of society. I don’t know how many people actually 
reach the last stage of universal ethical principles. 
 
However, I would like to say that in research integrity, I think, most or all of 
us are stuck in the stages of the child, teenager, young adult stage, and I 
think that’s worth thinking about. I actually even know examples of people 
who are still stuck in the infantile stage. 
 
What is research misconduct and  
how big a problem is it? 
 
How big a problem is it? Can I have a show of hands of people who know 
of practices they think are not correct? Seven out of thirty people. There you 
are. People were asked – this was published in Nature (Titus et al. 2008) – if 
they had observed or had direct evidence of research misconduct – and here 
it’s not the vague phrase I’ve used, but actual fabrication, falsification, pla-
giarism, serious research misconduct. 8.7% said they had observed it. Okay, 
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this is a survey and it may not be accurate. But I think, if anything, it is 
probably an underestimation. 
 
So what is research misconduct? There is no black and white. We often talk 
about serious research misconduct, which is fabrication, falsification, pla-
giarism. But then there are all these other practices which are now com-
monly termed as questionable research practices, like ignoring outliers in 
your data (data points that you don’t like – just forget about them), unde-
clared conflicts of interest, no data on side effects (I will keep them for a 
later paper), gift authorship. These are all transgressions in good research 
practice. If we take a different definition: ‘Questionable research practices’ 
is less than responsible conduct, it falls short of good research practice. 
There are a lot of issues that fall under that umbrella. 
 
Very few people will be in the area which is responsible conduct of re-
search, where you do absolutely everything correct. We are talking here 
about 10–15%. Very few people would also be in the very serious research 
misconduct area of fabrication, falsification, plagiarism. Estimations have 
been up to 1%, although I think in reality it’s probably slightly higher. But 
there’s a huge, fat middle bit where we talk about questionable research 
practices, and I think that’s an area we have to think much, much more 
about. There are all these spectacular cases that you’ve all heard about – 
Hwang from Korea, stem cell falsification, and so on. Yes, these are spec-
tacular cases. But I think we need to really look at this whole area of ques-
tionable research practices. 
 
Common transgressions 
 
As a framework there is integrity in research planning, conduct, analysis, 
and reporting. And publication ethics falls into the last category. But as edi-
tors, as I said before, we see often problems in all of these other areas be-
fore. 
 
What, for example, can go wrong in planning? Is my research needed? Re-
member our Kohlberg stages. Is that research I’m doing just for my CV, or 
is it research that really needs to be done? For example, is there enough 
animal data to do a first human study? You need to do a lot of research to 
know what your research question should be and what direction your re-
search should take. If you do a drug trial, are you using an inferior compara-
tor? That’s often done deliberately, of course, to make a new drug look bet-
ter. Is there a detailed protocol for the study you’re doing, including ethics 
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approval, a valid consent procedure, especially if you do research on hu-
mans? Is there an analysis plan? All these fall into the area of planning.  
 
Now, conduct of research. This is especially the case in randomised trials. Is 
there an adequate randomisation method? Have I maintained blinding? Is 
the patient consent procedure actually done as described? If you do more 
basic science research, how has the data collection been done? What hap-
pened to the lab books, case report forms, excel spreadsheets, etc.? These 
often kind of disappear, or are not to be found, or go up in fire, are eaten by 
white ants. I’ve heard all sorts of explanations as to how lab books, excel 
sheets, computers etc. disappear. Has there been regular oversight during the 
conduct of research? I’ll come back to that because I think that’s really im-
portant.  
 
Analyses – you now get your data. You don’t like some of the data? Get rid 
of the outliers. What happens to missing data? How to handle that? How 
many analyses have you done? Have you planned to do three or four analy-
ses or are you just analysing your data to death until you find a positive re-
sult because, yes, we all know that positive results are more likely to be 
published. Post hoc analyses – are they clearly defined as post hoc analyses? 
They are different, they are hypotheses-generating and they are not your 
main findings. At the Lancet, what we always do now with randomised, 
controlled trials, is to ask researchers to submit the protocol with the trial 
because then we can at least see what was planned. There are some odd 
cases where I have been sent a protocol that was written in the past tense. Or 
where the protocol was so different from the study that was submitted that I 
rang up the author and asked: “Have you sent the wrong protocol?” And he 
said: “No, no, no, but we found something completely different, so we’ve 
just sort of written it that way.” It was not written the way it was planned. 
Changing your endpoints: secondary are positive, primary are negative, just 
swap them around, makes it sound more exciting, doesn’t it? Omitting re-
sults, omitting adverse events – there are many, many possibilities, all of 
which I can assure you I’ve seen many times. 
 
In reporting, one of the forms of misconduct – and this might be slightly 
controversial – is failure to publish, to not publish at all. You’ve done your 
research, you didn’t like your results, it was not what you expected – you 
put it in a drawer. Why is that misconduct? If you have done research on 
people, or you have used animals or cells, you have a duty to bring it out 
there into the open. People always come back to me and say: “But you jour-
nals, you don’t publish this kind of unexciting results”. Which is true, I ad-
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mit that the Lancet probably is guilty of that. We do get after all 8000-9000 
submissions per year. We do publish negative data, too, but negative trial 
data only when it is an important negative. However, there are now so many 
web-based journals out there – there is even a Journal of Negative Results – 
where you can actually publish those results. It’s better to do so – even if it 
hasn’t got an impact factor of 20-something – than having your study disap-
pearing in a drawer. 
  
Now let us discuss authorship issues, and we’ll talk about that a little more 
carefully. Who did what is sometimes unclear. There are three Gs: ghost 
authors, guest authors or gift authors. Duplicate, redundancy, salami publi-
cation, that’s all part of the spectrum of the same theme. Plagiarism is on the 
rise. I think it’s partly because it’s just easy to do; electronically copying 
and pasting is just very easy. The concept of self plagiarism, where you 
have already published a review, an article or a paper with very similar re-
search and you actually just lift your whole discussion or your whole intro-
duction or your whole methods section and stick them into the new paper. Is 
anything wrong with that? Some people say no. I always get very annoyed 
as an editor when this happens, I have to say.  
 
Misleading reporting is very, very common, we see it all the time. There’s a 
big drug study, a pharmaceutical company funded study: the findings are 
negative. Then they torture the data with post hoc sub-analyses and the bot-
tom-line is: In the important subgroup X, Y, and Z, this drug works bril-
liantly. Or all side effects are reported in one little sentence somewhere. And 
we have to dig deep and ask the authors what were they, how many were 
there? Were they serious, were there minor side effects? This is the most 
common area, I would say, of publication ethics transgressions.  
 
Falsification and fabrication we see too, but these are rare. What does hap-
pen quite often, and that’s an interesting area, is figure manipulation. There 
are two types of figure manipulation. Again, it’s easy to do it now with 
Photoshop and so on. There’s the figure manipulation where you just make 
the picture look prettier, you change the contrast slightly or whatever. Well, 
that’s still manipulation, but it’s probably not influencing the data. But there 
is more sinister figure manipulation, as well, where a wrong band gets taken 
out and suddenly the results look much, much better than before. Some 
journals have started to screen for figure manipulation, especially in those 
papers they are planning to publish. And the figures there are quite stagger-
ing once again. They found in one study that about 20% of the figures were 
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manipulated to a certain degree. Half of those were manipulated in a way 
which actually changed the results. 
 
Plagiarism  
 
The answer I always get when I confront authors about plagiarism is either 
“Oh, I didn’t know there’s anything wrong with that” or “I’m reading so 
much that, just, you know, I don’t know how else to write it, how to write it 
differently”. I would like to challenge any of you to write a review twice 
within let’s say a framework of four or five months with exactly the same 
words. I think it would be a very good achievement if you could do that. So, 
again, that’s not an excuse I buy because I do think you have to actively 
copy and paste to get the same review word for word – a case I had very 
recently. Well, actually not word for word: he changed females to women. 
Omitted reference is another explanation we get and that usually applies if 
there is a little sentence which is taken word for word from a previous pub-
lication or from somebody else’s publication. And, you know, if it’s really 
only one sentence, we probably would say, ok that’s possible and we would 
then issue a correction rather than go down the route of investigating this 
person for misconduct. Who usually discovers plagiarism? Editors? Un-
likely, although we have done so in the past. Reviewers? They do some-
times, it depends. It can happen that it’s actually the person’s review that is 
plagiarized, the person we sent it to for review – fortunate for us editors, 
unfortunate for the author. Readers? They will definitely discover it eventu-
ally. The most common scenario is that we are contacted afterwards by 
readers who say: “Did you notice that this was very similar to a paper pub-
lished three years ago?” Plagiarism, again, but are all authors equally guilty? 
Not necessarily. It is often the first author who writes most of the paper or, 
in this case, plagiarized most of the paper. But we do challenge all the 
authors because we then get into the area of authorship questions. We had 
an interesting case where almost everyone in ophthalmology in Norway was 
named as author of a paper that was plagiarized from one of our review pa-
pers. The author in question clearly did the deed, but all the other authors 
who were listed on this paper, about ten or something like that, said they 
had nothing to do with the plagiarism. 
 
In future I think there will be software available to screen for plagiarism. At 
the moment, one in development is Crosscheck. It’s expensive, you have to 
pay per article screened and we would only do that, I think, for papers that 
we are intending to publish. It’s not yet fully developed because it needs 
many journals to sign up to it so that all their material can be screened and it 
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still means that the editor manually checks any manuscript that comes up 
with a high percentage of overlap. Free systems that are out there are either 
not good at all or not useful for us editors to screen. 
 
Authorship 
 
I said the three Gs. I’m sure that you all were once in that position on either 
the receiving or the giving end. The guest author says: “I’m the head of the 
department – I always have to be on the paper.” “I give you lab space – I 
have to be on the paper.” 
  
Gift authors, authorship as a present, is very common, we find, in Asian 
countries. I had this weird case where a Chinese paper was rejected by us 
and then I got rung up by Fiona Godlee, the British Medical Journal editor, 
and she said: “Your name is on a Chinese paper. I don’t quite know how 
this came about.” So I contacted the author and he said: “I just put you on 
the paper because you so kindly looked at my paper and rejected it.” And 
the story gets more bizarre. We contacted the author and said: “That’s not 
right. You can’t do that. I didn’t have any input in this paper other than 
reading it.” And then three weeks later Jeff Drazen from the New England 
Journal of Medicine emails me and Fiona Godlee, said: “Did you both know 
that you are on this paper from this Chinese author?” He didn’t quite get this 
message. 
 
Ghost authors, this is also very common. There is a peer review meeting 
held in Vancouver every four years. The most recent was in September and 
it was said that about 10% of all papers have so-called ghost authors. These 
are authors who have written the paper, usually medical writers from a 
company or a communication agency, and then are mentioned nowhere. We 
say they need to be at least mentioned in the acknowledgement section. De-
pending on how much they have done, they might be qualified for author-
ship. A year ago the Lancet started to ask every corresponding author of a 
paper before submission in our web submission system: “Was there a medi-
cal writer involved?”  So they have to say actively yes or no. If yes: who is 
it, what’s his or her name, and who funded this medical writer? Since then 
we have seen this much, much more often than when we didn’t ask that up-
front but just relied on authors to disclose the information. 
 
You are probably familiar with the authorship definitions. Not all journals 
go by these and the Lancet actually doesn’t. We have a contributor system 
by which we say: “You, the authors, it’s up to you as a group to decide who 
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is an author, you all have to agree, and then tell us who did what.” If it says 
XYZ has given the lab space, then it’s up to everyone to see that this person 
really isn’t mentioned as an author. The International Committee of Medical 
Journal Editors (ICMJE) has gone further with the authorship definition 
recently: Criteria are 1. substantial contribution to conception and design, or 
acquisition of data, or analysis and interpretation of data; 2. drafting the ar-
ticle or revising it critically for important intellectual content; and 3. final 
approval of the version to be published (1, 2, and 3 must all be met). All 
persons designated as authors should qualify for authorship and all those 
who qualify should be listed. Each author should have participated suffi-
ciently for an appropriate portion of the content as part of the attempt to 
further clarify authorship.  
 
Authorship is now difficult because it’s all team science, it’s cross-
disciplinary research. It is complex, we sometimes have twenty, thirty, 
sometimes forty authors – when you look at physics papers, there are hun-
dreds of authors. There is a pressure to publish, and authorship credit is pro-
fessional advancement. But I always urge you to decide at the beginning, at 
the outset of a study, at the planning stage, who should be an author and 
why and what should their roles be. What we also see infrequently is people 
wanting to take the glory, wanting to be an author but when something is 
found to be wrong with the paper actually not standing by it. We had a case 
last year with a group from Innsbruck where some authors said “I had noth-
ing to do with that” and, actually, it turned out in the investigation that they 
really had not much to do with it. They wanted to use the fact as a defence, 
but it is not a defence. You can’t take the glory without the responsibility. 
The journal Nature has tried to respond to the problem of authors not want-
ing to take responsibility when something has gone wrong by making the 
author in question sign something like (November 2007): “I have ensured 
that every author in my research group has seen and approved this manu-
script. The data that are presented in the figures and tables were reviewed in 
raw form, the analysis and statistics applied are appropriate and the figures 
are accurate representations of the data. All journal policies have been ad-
hered to. I have confidence that all of the conclusions presented are based on 
accurate extrapolations from the data collected for this study and that my 
colleagues listed as co-authors have contributed and deserve the designation 
‘author’.” They wanted the author to actually sign this statement, but there 
was a lot of disquiet about the suggestion and, as far as I know, they have 
not enforced it. 
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Duplicate, redundant, salami publication 
 
Salami publication, this more or less means: slice the thinnest slice you can 
get away with to make as many papers out of a salami that you possibly can. 
Redundant as well as overlap. You have twenty data points and you have 
ten more, so you publish your first twenty and then publish a paper with 
thirty afterwards, and so on. Duplicates mean purely trying to republish 
what was published before. And this is almost always inappropriate. There 
are exceptions. The exception is if you want to publish something again in a 
different language. To some extent you can justify some of the salami type 
of publication if there is a very different readership, for example, when you 
publish main trial data with clinical outcomes and you publish the immu-
nological outcomes as well, although increasingly journals don’t like that 
anymore. We want to see the whole picture. We want to see primary and 
secondary outcomes. We want so see quality of life data in the main paper. 
We want to see the whole picture together. Because people try to publish 
when there are two primary outcomes, they try to publish two different pa-
pers from that and that’s absolutely inappropriate. But I believe that a solu-
tion is simply to have maximum transparency. Speak to the editor, tell him: 
“This has already been published and now I want to publish this part.” Or 
talk to people, let them know. Editors may say: “Yes, that’s OK. I’ll buy 
that, as long as it’s referenced, as long as it is out there, people can make a 
decision.” 
 
Conflict of interest, role of sponsor 
 
This is a big area again. Often people say: “I don’t have a conflict.” I hear 
all sorts of funny stories about conflicts of interest. People honestly write to 
us and say: “I’m funded by pharmaceutical companies A, B, C, D, E and F, 
so I’m funded by everyone, so I don’t have a conflict of interest. “I don’t 
have a perceived conflict of interest.” . Perceived by whom? The author 
obviously wants to just gloss over something. So again, the conflict of inter-
est – easy, just be one hundred percent transparent about it, say everything 
you do, say everything, declare all the money you get, everyone who spon-
sors you. It’s not up to you to decide whether this is a conflict or not. The 
word conflict is slightly difficult and some journals say: “We call it compet-
ing interest.” Or maybe there are better words to come in the future. How-
ever, I believe authors who represent a certain point of view must explain 
their position very clearly. The same is needed with the role of sponsors. 
What did the sponsors do? Did they analyse the data? Obviously that needs 
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to be known because there is a difference between the ways I look at it and 
reviewers look at it. We say that of course all authors should have access to 
the data as a prerequisite. Another journal went slightly further and said they 
want to have independent statistical analyses of all company sponsored tri-
als. Since they introduced this rule about three years ago, their trial publica-
tions have plummeted. It is difficult to say companies’ statisticians can’t do 
their job as well as an independent statistician. And often company trials are 
run better than independent trials. So I don’t think you can say that just be-
cause there is a pharmaceutical company involved that something fishy is 
going on. But I think transparency is the key, again. 
 
Solutions 
 
The best way to handle misconduct is via the institutions. It’s good to have a 
clearly defined person as the first point of contact. It’s terrible when I have 
a doubt and I don’t even know whom to contact at the institution or at the 
university. In the USA, every institution has a Research Integrity Officer. 
Due process is really important. Have a process in place by which any alle-
gations are investigated. The investigation should be fair and ideally speedy. 
In my experience, serious allegation investigations take up to a year, the 
quicker ones perhaps six months but I have never seen anything under six 
months. And ideally it should be an independent investigation by someone 
who is outside the university or at least a chair who is outside the university. 
I think the results need to be made publicly available. I had enormous trou-
bles last year with an Austrian case in which the Austrian agency said: “Oh, 
we can’t publish that for legal reasons.” So I have all these documents, but 
they couldn’t be published for legal reasons. It makes it very difficult then 
to justify retracting a paper. Then: work with and inform all relevant 
stakeholders, journals - there might be more than one journal involved – and 
funders. And I think one of the areas that is often not handled well is the 
protection of whistleblowers. Have a clear pathway for whistleblowers, for 
what they can do if they’ve seen something that shouldn’t happen. After-
wards there should be appropriate sanctions and consequences. That might 
be obvious, but very often it isn’t the case. But we should go further and, 
once the case has happened, there should be lessons for continuing culture 
change within an institution. Ideally a country should also have national 
bodies to oversee or perhaps help in conducting independent investigations. 
The Scandinavian countries are very good at having these national bodies. 
 
Editors – how to handle misconduct? I think the first role is for us not to just 
reject the paper when it’s only submitted. When it’s published we have a 
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duty to do something with the paper because we actually have to correct the 
published record. But when the paper is just submitted and it looks a bit 
odd, the common way to deal with it is to just reject it. What often happens 
then, is that it is published somewhere else. It gets published in a journal 
that doesn’t have as many editors as the Lancet does and where there isn’t 
as much time to follow up on these cases. Again, it should be our duty that 
authors should be challenged first and, if it’s serious and I am not satisfied 
with their reaction, my duty as an editor is to go to the institution in ques-
tion. I cannot investigate, I don’t know what’s going on in that research en-
terprise. That needs to be done by the institution. So, we are instigating the 
investigation and then acting on the findings, including retraction if appro-
priate for a published paper. There is always a question about banning 
authors but that’s very problematic. How do we do that? Which of the 
authors and for how long? We actually don’t do that, but we all have a very 
long institutional memory that’s not written down anywhere. In addition, 
there is the Committee on Publication Ethics (COPE) where we meet every 
three months and discuss difficult cases anonymously and give each other 
advice on what to do. 
 
How to foster integrity? 
 
I believe it is really important to foster integrity. Not only react to bad cases 
but also try to prevent them from happening in the first place. There should 
be clarity in reporting, which makes it a lot easier. Also, authors are aware 
that, when they give all this information, it will make it a lot easier for me to 
see if something is wrong. There should be promotion of honesty and trans-
parency. I think I’ve used that word many times already. Transparency is 
key. In terms of protocols, ethics approval, trial registration, statements. 
Some journals have gone down the route of screening, which has the advan-
tage that you wouldn’t publish something that has been plagiarized or fig-
ures that have been manipulated. It has the added advantage that it acts as a 
deterrent. Because if an author knows that a particular journal is screening, 
it would be stupid to manipulate figures. We can write editorials and com-
mentaries on the issue – and we do that.  
 
How to foster integrity at institutions? I think there should be guidelines 
covering all aspects of research. But many universities have guidelines and 
when you look at them it looks like there are guidelines all over the place. 
But what is often lacking are clear consequences. What happens if people 
don’t follow these guidelines? There should be mandatory education in re-
sponsible conduct of research. I think it’s happening more and more at the 
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student level, but I believe it should also include all researchers, including 
professors. There should be effective and responsible mentoring in terms of 
role models. That is very important. Remember an environment of integrity 
is important. It would be great if, somehow, all studies that are in progress 
or planned, or are done could be centrally documented in terms of study 
protocols. And it would be great to have central storage of raw data or lab 
book data. Random checks and audits of ongoing research I think is a very 
good idea. Again, this may mean that you might find something early on 
and not some six or ten years after it’s published. In addition, it acts as a 
deterrent. People know that they might be subjected to random checks and 
might not feel as comfortable to manipulate some of their data. Clear and 
transparent policies, especially in the areas of conflict of interest and intel-
lectual property, I think are very important at an institutional level. I want to 
leave you now with just one thought. The loss of reputation is a really seri-
ous and widely underestimated risk for universities. So I do believe that 
universities need to make fostering and guarding research integrity part of a 
discussion on their risk management strategy. 
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View from the Bench-Side 
 
by Irene Knüsel 
 
Where do we go from here? Is there anything left to say? We have all been 
confronted with numerous statements, facts and figures on various forms 
and shades of scientific misconduct, starting with ethically questionable 
research objectives and methods, unjustified expectations and misinterpreta-
tions, on to exclusion, loss, manipulation and even fabrication of scientific 
data. Some of us were shocked or embarrassed, others still in complete de-
nial, a few perhaps relieved to hear that the majority of scientists actually 
does follow good laboratory practice and performs not only honest but also 
excellent scientific work. And, fortunately, there are solutions: hundreds of 
pages with recommendations and guidelines on teaching and education with 
respect to handling misconduct in scientific research. Ombudspersons or 
research integrity officers have been trained and appointed to provide re-
search institutions as well as political authorities with advice on basic ques-
tions concerning scientific integrity. Problem solved – we have everything 
under control, let’s go back to the bench! 
 
Problem really solved?  
 
But why, then, does cheating and manipulating data in science still occur? 
Worse yet, it is not as rare as we all thought and, if we believe the pessi-
mists, there is an upward trend. Quite possibly, we have not completely 
solved the issue of responsibility, liability or even penalties and sanctions. 
For punishment, however, we usually opt for the easy solution: find the stu-
dents who did the experiments and kick them out and, if necessary, with-
draw their degrees. That ought to inhibit further misbehaviour as efficiently 
and thoroughly as our legal precautions prevent criminal behaviour within 
our society. Or is the situation a bit more complex? 
 
Who does the cheating?  
 
A first step is to identify and understand the type of people who are actually 
guilty of or prone to dishonest scientific behaviour. It is important to keep in 
mind that scientists do not belong to a different species of humans but con-
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stitute the same variety of people with unique characters, strengths and 
weaknesses as in any other professional group. There will always be a few 
individuals with innate criminal energy, prone to any form of misconduct 
and misbehaviour. This type will certainly not be frightened by a memoran-
dum on scientific integrity; however, as we have learnt from the past, their 
cheating sooner or later will rise to the surface. On the other end of the bell 
curve there are individuals with the highest moral and ethical standards, the 
Gandhis and Dalai Lamas of scientific research who need no guidelines or 
procedural rules. This leaves the large group between these two extremes, 
the people who aim for excellence in science, strive for the big breakthrough 
and are driven by a unique intellectual curiosity necessary to withstand the 
setbacks and frustrations in scientific research. Of course researchers also 
strive for recognition and admiration, a trait which to various degrees can be 
intermingled with pronounced competition for power, influence and money. 
Again, this is nothing unique to the world of science. This possibly repre-
sents an aggravating factor, but is not likely the cause for scientific miscon-
duct. It rather appears as though the scientific environment, in addition to 
forming new Gandhis and Dalai Lamas, is equally capable of pushing a few 
individuals into another direction, despite the well-known regulations and 
legal consequences. 
 
Science as a crowded highway  
 
Quite possibly, scientists behave as irrationally as people do in anonymous 
crowds and when under pressure. Science today is somewhat like driving on 
a busy highway. Sitting in your fancy sports car, you might be in a hurry to 
get to your next meeting, you might be the type who enjoys any form of 
competition, so you increase your speed, test what your car can do, make it 
a race. You know very well that the speed limit is 120 kph, and that you 
might lose your license. But everyone is driving too fast – so it can’t be too 
wrong. The flow of traffic keeps you moving, and, indeed, you would en-
danger others by driving only 80 kph or stepping on the brakes. And, after 
all, the speed limit is silly because your driving is so skilful. You tell your-
self that you will reduce your speed and drive safely once you have reached 
your destination. You just need to pass the others right now on this very 
busy and very crowded highway before it morphs into a traffic jam and 
someone else wins the race.   
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Up or out 
 
To a certain extent, the jammed highway depicts the situation we scientists 
are currently in: the fight for financial support for research projects and in-
creasing numbers of excellent scientists applying for limited amounts of 
money. We feel pressure to publish our work in high-impact scientific jour-
nals and, ideally, have a major break-through every year that hopefully will 
facilitate further fund-raising and expand the research team. Competition 
rages among research groups worldwide. This is all good – as a matter of 
fact, it is excellent. We honestly need this competition to move science for-
ward, to discover new principles and to understand the laws of nature. Jour-
nals ought to accept only the best data because that is what maintains moti-
vation and alertness. What is not necessary, however, is an indiscriminate 
belief in a causal relationship between the number of publications in prestig-
ious journals and professional qualifications. Of course there is a strong 
positive correlation, but there are well-known facts like “not-so-great-
scientific-content-in-great-journal” and “great-scientific-content-in-not-so-
great-journal” that distort this simple qualification ratio. And I believe this 
is one of the possible reasons why scientists cheat: there is a growing toler-
ance for speeding when moving from A to B, in getting tenure, the perma-
nent position, or a professorship at a prestigious university. Under enough 
pressure, some individuals might do anything it takes to achieve what they 
have always wanted and dreamed of. And, if the situation is either up or out, 
break-through or break-down, you will speed up your car because others are 
also driving too fast – or even faster. 
 
Getting the best 
 
Some people may argue that the system regulates itself, that this is exactly 
the way the best candidates succeed: natural selection and survival of the 
fittest. The question is, however, the best and fittest at what? Who is 
screened in this selection process and how is the screening done? The can-
didates with the fanciest, newest or fastest cars or rather the rudest drivers? 
Universities need excellent scientists and excellent teachers but also excel-
lent role models; this cannot always be found in one and the same person. A 
fair appointment and promotion system based on sophisticated qualification 
requirements is necessary. In addition, support and infrastructure could be 
provided according to potential and talent. Give the scientists their lab and 
let them do what they do best – research – and reduce their duties in admini-
stration, personnel management and teaching. These duties could be filled 
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by other qualified scientists who – beside their own research – have interest 
and ability in teaching, training and supervising students and who can take 
on management duties. This would at the same time facilitate brainstorming, 
the exchange of ideas and real teamwork, thus providing a more efficient 
way of getting from A to B – a type of car-sharing in scientific terms. Such 
a system would alleviate some of the pressure and many individuals could 
find ideal alternatives within science and research in academia. And, hope-
fully, scientists would be hired because someone has actually read – and not 
just counted – their publications.  
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